These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 24464803

  • 21. Development and validation of a RP-HPLC method for the quantitation of tofacitinib in rat plasma and its application to a pharmacokinetic study.
    S VK, Dhiman V, Giri KK, Sharma K, Zainuddin M, Mullangi R.
    Biomed Chromatogr; 2015 Sep; 29(9):1325-9. PubMed ID: 25622797
    [Abstract] [Full Text] [Related]

  • 22. Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes.
    Nebot N, Crettol S, d'Esposito F, Tattam B, Hibbs DE, Murray M.
    Br J Pharmacol; 2010 Nov; 161(5):1059-69. PubMed ID: 20977456
    [Abstract] [Full Text] [Related]

  • 23. Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release Tofacitinib.
    Lamba M, Hutmacher MM, Furst DE, Dikranian A, Dowty ME, Conrado D, Stock T, Nduaka C, Cook J, Krishnaswami S.
    Clin Pharmacol Ther; 2017 Jun; 101(6):745-753. PubMed ID: 27859030
    [Abstract] [Full Text] [Related]

  • 24. Metabolism, pharmacokinetics, and excretion of the substance P receptor antagonist CP-122,721 in humans: structural characterization of the novel major circulating metabolite 5-trifluoromethoxy salicylic acid by high-performance liquid chromatography-tandem mass spectrometry and NMR spectroscopy.
    Colizza K, Awad M, Kamel A.
    Drug Metab Dispos; 2007 Jun; 35(6):884-97. PubMed ID: 17360832
    [Abstract] [Full Text] [Related]

  • 25. Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment.
    Veeravalli V, Dash RP, Thomas JA, Babu RJ, Madgula LMV, Srinivas NR.
    Drug Saf; 2020 Aug; 43(8):711-725. PubMed ID: 32367507
    [Abstract] [Full Text] [Related]

  • 26. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes.
    Murayama N, Imai N, Nakane T, Shimizu M, Yamazaki H.
    Biochem Pharmacol; 2007 Jun 15; 73(12):2020-6. PubMed ID: 17433262
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers.
    Johne A, Scheible H, Becker A, van Lier JJ, Wolna P, Meyring M.
    Invest New Drugs; 2020 Oct 15; 38(5):1507-1519. PubMed ID: 32221754
    [Abstract] [Full Text] [Related]

  • 30. The Metabolism and Disposition of Brepocitinib in Humans and Characterization of the Formation Mechanism of an Aminopyridine Metabolite.
    Dowty ME, Qiu R, Dantonio A, Niosi M, Doran A, Balesano A, Wright SW, Walker GS, Sharma R.
    Drug Metab Dispos; 2024 Jun 17; 52(7):690-702. PubMed ID: 38719744
    [Abstract] [Full Text] [Related]

  • 31. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.
    Vincent SH, Reed JR, Bergman AJ, Elmore CS, Zhu B, Xu S, Ebel D, Larson P, Zeng W, Chen L, Dilzer S, Lasseter K, Gottesdiener K, Wagner JA, Herman GA.
    Drug Metab Dispos; 2007 Apr 17; 35(4):533-8. PubMed ID: 17220239
    [Abstract] [Full Text] [Related]

  • 32. Evaluation of metabolism and disposition of GDC-0152 in rats using 14C labeling strategy at two different positions: a novel formation of hippuric acid from 4-phenyl-5-amino-1,2,3-thiadiazole.
    Yue Q, Mulder T, Rudewicz PJ, Solon E, Budha N, Ware JA, Lyssikatos J, Hop CE, Wong H, Khojasteh SC.
    Drug Metab Dispos; 2013 Feb 17; 41(2):508-17. PubMed ID: 23223496
    [Abstract] [Full Text] [Related]

  • 33. In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition.
    Gallemann D, Wimmer E, Höfer CC, Freisleben A, Fluck M, Ladstetter B, Dolgos H.
    Drug Metab Dispos; 2010 Jun 17; 38(6):905-16. PubMed ID: 20219851
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Excretion, metabolism, and pharmacokinetics of 1-(8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)-4-(ethylamino)piperidine-4-carboxamide, a selective cannabinoid receptor antagonist, in healthy male volunteers.
    Miao Z, Sun H, Liras J, Prakash C.
    Drug Metab Dispos; 2012 Mar 17; 40(3):568-78. PubMed ID: 22187487
    [Abstract] [Full Text] [Related]

  • 36. Phase 1 Dose-Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers.
    Miyoshi S, Krishnaswami S, Toyoizumi S, Nakamura H, Zwillich SH.
    Clin Pharmacol Drug Dev; 2020 Jan 17; 9(1):11-20. PubMed ID: 31713350
    [Abstract] [Full Text] [Related]

  • 37. An evaluation of tofacitinib for the treatment of psoriatic arthritis.
    Abdulrahim H, Sharlala H, Adebajo AO.
    Expert Opin Pharmacother; 2019 Nov 17; 20(16):1953-1960. PubMed ID: 31456440
    [Abstract] [Full Text] [Related]

  • 38. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3.
    Yanni SB, Annaert PP, Augustijns P, Ibrahim JG, Benjamin DK, Thakker DR.
    Drug Metab Dispos; 2010 Jan 17; 38(1):25-31. PubMed ID: 19841059
    [Abstract] [Full Text] [Related]

  • 39. Aggression behaviour induced by oral administration of the Janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditions.
    Fukuyama T, Tschernig T, Qi Y, Volmer DA, Bäumer W.
    Eur J Pharmacol; 2015 Oct 05; 764():278-282. PubMed ID: 26164790
    [Abstract] [Full Text] [Related]

  • 40. Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study.
    Ruperto N, Brunner HI, Zuber Z, Tzaribachev N, Kingsbury DJ, Foeldvari I, Horneff G, Smolewska E, Vehe RK, Hazra A, Wang R, Mebus CA, Alvey C, Lamba M, Krishnaswami S, Stock TC, Wang M, Suehiro R, Martini A, Lovell DJ, Pediatric Rheumatology International Trials Organization (PRINTO), Pediatric Rheumatology Collaborative Study Group (PRCSG).
    Pediatr Rheumatol Online J; 2017 Dec 28; 15(1):86. PubMed ID: 29282090
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.